Literature DB >> 18716745

Disseminated intravascular coagulation: current concepts.

R Kumar1, V Gupta.   

Abstract

Disseminated intravascular coagulation (DIC) is an acquired disorder in which normal hemostatic balance is disturbed. There is excessive thrombin formation leading to fibrin deposition in microcirculation and consequent ischemic organ damage. The etiology is multifactorial. A number of medical, surgical, oncological and obstetrical conditions can cause DIC. The diagnosis is essentially clinical supported by laboratory parameters and a scoring system based on these. The mainstay of treatment is correction of underlying cause and hemostatic support with replacement of coagulation factors. The role of heparin therapy and other therapeutic options including activated protein C, antithrombin III etc. have also been discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18716745     DOI: 10.1007/s12098-008-0139-x

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  16 in total

Review 1.  Disseminated intravascular coagulation.

Authors:  M Levi; H Ten Cate
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

2.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

3.  Is protease inhibitor a choice for the treatment of pre- or mild disseminated intravascular coagulation?

Authors:  T Nishiyama; T Matsukawa; K Hanaoka
Journal:  Crit Care Med       Date:  2000-05       Impact factor: 7.598

4.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

Review 5.  Disseminated intravascular coagulation: diagnosis and treatment.

Authors:  T Baglin
Journal:  BMJ       Date:  1996-03-16

6.  ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis.

Authors:  Brahm Goldstein; Simon Nadel; Mark Peters; Roger Barton; Flavia Machado; Howard Levy; Douglas J Haney; Barbara Utterback; Mark D Williams; Brett P Giroir
Journal:  Pediatr Crit Care Med       Date:  2006-05       Impact factor: 3.624

7.  Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

Authors:  J Kienast; M Juers; C J Wiedermann; J N Hoffmann; H Ostermann; R Strauss; H-O Keinecke; B L Warren; S M Opal
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

8.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

9.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

Authors:  Edward Abraham; Konrad Reinhart; Steven Opal; Ignace Demeyer; Christopher Doig; Angel López Rodriguez; Richard Beale; Petr Svoboda; Pierre Francois Laterre; Stuart Simon; Bruce Light; Herbert Spapen; Judy Stone; Allan Seibert; Claus Peckelsen; Cathy De Deyne; Russell Postier; Ville Pettilä; Charles L Sprung; Antonio Artigas; Sandra R Percell; Vincent Shu; Christian Zwingelstein; Jeffrey Tobias; Lona Poole; James C Stolzenbach; Abla A Creasey
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

Review 10.  Practical aspects of treatment with drotrecogin alfa (activated).

Authors:  Luigi Camporota; Duncan Wyncoll
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.